TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02989571

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous normal saline administered at 250ml/hr
Description: Intravenous normal saline administered at 250ml/hr

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous normal saline administered at 125ml/hr
Description: Intravenous normal saline administered at 125ml/hr
Study: NCT04633954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine Tartrate 0.15% Oph Soln
Description: One drop of Brimonidine Tartrate 0.15% Oph Soln prior to FLACS
Study: NCT04067349

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ergometry
Description: Patients underwent a preoperative ergometry to assess their physical fitness prior to their planned liver resection.~Bicycle stress testing was performed preoperatively and 1 and 6 months postoperatively.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ergometry
Description: Patients underwent a preoperative ergometry to assess their physical fitness prior to their planned liver resection.~Bicycle stress testing was performed preoperatively and 1 and 6 months postoperatively.
Study: NCT04710186

Intervention type: PROCEDURE
Intervention: arterial reconstructive open surgery
Description: Patients with peripheral artery disease (PAD) will undergo arterial reconstructive open surgery. Samples obtained from diseased arteries of lower limbs of patients undergoing arterial reconstructive open surgery will be collected and immediately preserved at -80°. Briefly, arterial tissues were excised, homogenized using a motor driven homogenizer and total RNA was isolated using Trizol reagent (Invitrogen, Milan, Italy), in accordance with the manufacturer's instructions. The expression of Androgen Receptor (AR), insulin receptor (IR) and the IGF-I receptor (IGF-IR) will be quantified by real-time PCR using platform Quant Studio7 Flex Real-Time PCR System (Thermo Fisher Scientific, Milan, Italy), following the manufacturer's instructions.
Study: NCT00542932

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Watched Film A (promotional film)~Film B (30 min exercise video) asked to to perform 4 times a week for 6 weeks at home
Study: NCT03441945

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: magnetic steering
Description: magnetic steering
Study: NCT01324739

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human BNP-32
Description: 3pmol/kg/min infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: human BNP-32
Description: 3pmol/kg/min infusion
Study: NCT02202109

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CHW and Self-sampling for Cervical Cancer
Description: Behavioral: CHW and Self-sampling for Cervical Cancer The intervention strategies will involve one home visit: 1) provide brief health education on cervical cancer screening, 2) provide and collect self-sampler test. We envision visits lasting no more than 60 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mailed Self Sampler
Description: Mailed Self Sampler. Women randomized to this intervention arm will receive a self-sampling kit via mail. This kit will include: 1) the self-sampler; 2) the vial for collecting and storing the specimen; 3) a pre-addressed, stamped envelope for returning the vial; 4) a brief introductory letter/postcard which includes a picture of the CHE and the CHW and serves to re-orient the participant to the focus of the study; 5) instructional guide that visually depicts the steps for self-sampling;
Study: NCT00467298

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise adherence
Description: The exercise program includes endurance and strength training and warm-up and cool-down strategies. Emphasis is placed upon implementing and adhering to the exercise program at home following intervention completion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management- prevention of illness
Description: Instruction is provided regarding key elements of managing heart failure and COPD with emphasis upon individual adaptations to prevent exacerbations, unscheduled provider visits, and hospital admissions as well as promotion of daily activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management of illness
Description: This component of the intervention stresses the use of an action plan that is implemented to c-manage bouts of mild illness and to identify symptoms of more serious illness, including appropriate actions.
Study: NCT02836262

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIT Hip Replacement System
Description: HIT Hip Replacement System
Study: NCT00665132

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StimRouter System
Description: Implanted with StimRouter System receive 6 hours (or less if not tolerated by the Subject)of electrical therapeutic stimulation each day for a total of 5 days (from start of successful programming)
Study: NCT04338906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camostat Mesilate
Description: 400 mg tid, d1-d7

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Instead of Camostat Mesilate, tid, d1-d7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 400 mg bid on day 1, 200 mg bid d2-d7

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: 400 mg bid on day 1, 200 mg bid d2-d7
Study: NCT02482532

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tvs-CTL Vaccine
Description: autologous, 14g2a.zeta chimeric receptor transduced, activated T-cells, enriched for vaccine specific cytotoxic T-lymphocytes (tvs-CTL)
Study: NCT00361036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uterine fibroid embolization BeadBlock™
Description: Intervention with BeadBlock Microspehere

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Uterine fibroid embolization Embosphere®
Description: Embosphere - control arm
Study: NCT01955759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone tab 200 mg x 3
Description: starting 7 days before coronary by-pass surgery per os 200 mg. x 3 tab, followed by 200 mg x 2 tab per os starting on the second postoperative day untill discharge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg tab x1
Description: starting 7 days before coronary by-pass surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: beta blockers Bisoprolol in adjusted dose
Description: starting 7 days befoe coronary by-pass surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beta blockers Bisoprolol in adjusted dose
Description: starting 7 days befoe coronary by-pass surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beta blockers Bisoprolol in adjusted dose
Description: starting 7 days befoe coronary by-pass surgery
Study: NCT03345147

Intervention type: OTHER
Intervention: High Vitamin A intake
Description: Total Vitamin A stores will be assessed by isotopic measurement, 13C-Retinol will be given to the subject and blood wil be drawn on Day 4 to assess the isotopic dilution in the plasma. Other biochemical indicators will be assessed too, along with Dietary assessment (Food Frequency, 24 hours recalls).

Intervention type: OTHER
Intervention: Normal Vitamin A intake
Description: Total Vitamin A stores will be assessed by isotopic measurement, 13C-Retinol will be given to the subject and blood wil be drawn on Day 4 to assess the isotopic dilution in the plasma. Other biochemical indicators will be assessed too, along with Dietary assessment (Food Frequency, 24 hours recalls).
Study: NCT03888222

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Fifteen (15) patients in group 1 will receive the matching placebo(sugar pill) one (1) tablet orally once daily for 3 months (90 days) .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bosutinib Oral Tablet
Description: Fifteen (15) patients in group 1 will receive the 100 mg of Bosutinib one (1) tablet orally once daily for 3 months (90 days) .
Study: NCT04256369

Intervention type: COMBINATION_PRODUCT
Intervention: Parenteral Nutrition (PN) Premixed Olimel N9E
Description: Parenteral nutrition
Study: NCT04224454

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire was adapted from questionnaires used by the French national agency Institut de Veille Sanitaire to study vaccination coverage and were completed with the assistance of one fellow to limit missing data.
Study: NCT01814436

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: scaffold-free SHED-derived pellet
Description: The purpose of this clinical trial is to both clarify the efficiency of autologous SHED to regenerate pulp and periodontal tissue in the patients with avulsed immature permanent teeth and pulp necrosis to confirm the safety of using autologous stem cells in clinical endodontic regenerative medicine.
Study: NCT02582398

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light Therapy
Description: One subgroup of SAD patients and healthy controls respectively will receive bright light therapy using an artificial white light source (PhysioLight LD220 by DAVITA®, www.davita.de/shop/lichttherapiegeraete/lichtduschen-tageslicht/physiolight-ld-220.html) with full-spectrum 10.000lux light intensity. The treatment will be applied 30min per day at a distance of about of 50cm, preferably in the morning, during 3 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Light
Description: The second subgroup of the SAD patients and healthy controls will receive a non-biologically active light source (\<400nm or \>500nm). Here, the lamp will have largely similar shape and size as compared to the therapeutic device, but the fluorescent tube with the high light intensity will be replaced by an ordinary bulb.
Study: NCT02561078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human regular U-500 insulin (CSII)
Description: Administered SC
Study: NCT02787057

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: oral moxifloxacin 400mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftazidime
Description: IP ceftazidime 1g QD
Study: NCT01524068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Steroid Treatment
Description: One gm of methylprednisolone i.v., on day 0, followed by 40 mg/day i.v. on days 1-4, and days 6-12 (or the p.o. prednisone equivalent). Methylprednisolone 100 mg i.v. will be administered on days 5 and 13. Steroid doses will then be 20 mg methylprednisolone i.v. (or p.o. prednisone equivalent) from days 14-28, and then reduced thereafter at the discretion of the PI at each site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The Standard Steroid Treatment, Plasma Exchange and rituximab
Description: The Standard Steroid Treatment and, after insertion of a dialysis/apheresis catheter into a central vein, followed by initiation of the PEX and rituximab regimens.
Study: NCT03759145

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergame
Description: Participants use exergame with the therapist in the rehabilitation center. Several games are available, the therapist adjusts the choice of game and level of difficulty according to the participant's abilities and interests.

Intervention type: OTHER
Group type: OTHER
Intervention: usual care
Description: participants continued their planned rehabilitation sessions
Study: NCT02468713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combiflex® lipid peri
Description: total parenteral nutrition solutions containing glucose, amino acids, electrolyte, soybean oil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combiflex® lipid peri
Description: total parenteral nutrition solutions containing glucose, amino acids, electrolyte, soybean oil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Winuf® peri
Description: total parenteral nutrition solution containing glucose, amino acids, electrolyte, soybean oil, medium chain triglyceride, olive oil and fish oil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Winuf® peri
Description: total parenteral nutrition solution containing glucose, amino acids, electrolyte, soybean oil, medium chain triglyceride, olive oil and fish oil
Study: NCT00464555

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Islet transplant
Description: Transplantation of pancreatic islet cells
Study: NCT02561078

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human regular U-500 insulin (MDI)
Description: Administered SC
Study: NCT04037345

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SMUP-IA-01(low-dose)
Description: A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10\^6 cells/2mL)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SMUP-IA-01(mid-dose)
Description: A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10\^7 cells/2mL)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SMUP-IA-01(high-dose)
Description: A single knee administration of SMUP-IA-01(high-dose, 2.0 x 10\^7 cells/2mL)
Study: NCT03893006

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Level of vehicle automation
Description: From no automation of the vehicle to full automation through warnings, shared control and partly automated automation levels.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Level of vehicle automation
Description: From no automation of the vehicle to full automation through warnings, shared control and partly automated automation levels.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Level of vehicle automation
Description: From no automation of the vehicle to full automation through warnings, shared control and partly automated automation levels.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Level of vehicle automation
Description: From no automation of the vehicle to full automation through warnings, shared control and partly automated automation levels.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Level of vehicle automation
Description: From no automation of the vehicle to full automation through warnings, shared control and partly automated automation levels.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Level of vehicle automation
Description: From no automation of the vehicle to full automation through warnings, shared control and partly automated automation levels.
Study: NCT01501292

Intervention type: OTHER
Intervention: Fixation and staining
Description: Fixation and staining by MitiTracker Green FM

Intervention type: OTHER
Intervention: Fixation and staining
Description: Fixation and staining by MitiTracker Green FM

Intervention type: OTHER
Intervention: Observation by laser microscopy
Description: Observation with Laser scanning confocal microscopy

Intervention type: OTHER
Intervention: Observation by laser microscopy
Description: Observation with Laser scanning confocal microscopy
Study: NCT03787420

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: communication system
Description: We will use the questionnaire Amyotrophic Lateral Sclerosis Supportive Care Needs ,Amyotrophic Lateral Sclerosis Specific Quality of Life Instrument-Revised, Beck Depression Inventory and Caregiver Burden Scale.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: communication system
Description: We will use the questionnaire Amyotrophic Lateral Sclerosis Supportive Care Needs ,Amyotrophic Lateral Sclerosis Specific Quality of Life Instrument-Revised, Beck Depression Inventory and Caregiver Burden Scale.
Study: NCT03484299

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Irreversible Electroporation (IRE)
Description: Non-thermal ablation of tumor

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: 25% dose - first 3 enrolled; 50% dose - next 3 enrolled; 75% dose - remaining 4 enrolled

Intervention type: DRUG
Group type: OTHER
Intervention: FOLFIRINOX
Description: 25% dose - first 3 enrolled; 50% dose - next 3 enrolled; 75% dose - remaining 4 enrolled
Study: NCT02459405

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NIR anastomotic perfusion assessment
Description: Patient will have their anastomosis assessed by near infrared technology after indocyanine green has been injected i.v. The procedure will be repeated twice, once before the anastomosis and the second time after the anastomosis has been performed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near infrared camera
Description: Use of the Pinpoint laparoscopic scope (Novadaq, Vancouver, Canada) after injection of indocyanine green
Study: NCT00348868

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: enhanced behavioral motivation counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational counseling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard counseling
Study: NCT05005286

Intervention type: OTHER
Intervention: Past history of vaginal Infections
Description: With or without vaginal infection during pregnancy
Study: NCT02759237

Intervention type: DEVICE
Intervention: CoreValve System Family
Description: Bioprosthesis: Transcatheter Aortic Valve Implant (TAV - Heart Valve) -Different Models/Sizes of CoreValve/CoreValve Evolut R.~Delivery Catheter System: ACCUTRAK \& EnVeo R - Used to facilitate the placement of the bioprosthesis within the annulus.~Loading System: Compression Loading System \& EnVeo R Loading System - Used to load the TAV onto the delivery system
Study: NCT01222533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium medium
Description: Tiotropium inhalation solution medium dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium low
Description: Tiotropium inhalation solution low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium high
Description: Tiotropium inhalation solution high dose
Study: NCT00464555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin
Description: Immunosuppressive that selectively depletes activated T-cells and depletes resting T-cells in a dose-dependent manner.
Study: NCT01222533

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium 18mcg
Description: Tiotropium inhalation powder 18mcg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tiotropium placebo
Description: Placebo inhalation solution
Study: NCT01947517

Intervention type: DEVICE
Intervention: Parasol Punctal Occluder
Description: Patients will be randomized to receive one of these 2 punctal occluders in the management of dry eyes.

Intervention type: DEVICE
Intervention: Superflex Punctal Occluder
Description: Patients will be randomized to receive one of these 2 punctal occluders in the management of dry eyes.
Study: NCT00867178

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo conformal radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo PBSC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study: NCT02276638

Intervention type: DEVICE
Intervention: Specular Microscope Nidek CEM-530
Description: Nidek CEM-530

Intervention type: DEVICE
Intervention: Specular Microscope Nidek CEM-530
Description: Nidek CEM-530

Intervention type: DEVICE
Intervention: Specular Microscope Nidek CEM-530
Description: Nidek CEM-530

Intervention type: DEVICE
Intervention: Specular Microscope Konan CELLCHEK XL
Description: Konan CELLCHEK XL

Intervention type: DEVICE
Intervention: Specular Microscope Konan CELLCHEK XL
Description: Konan CELLCHEK XL

Intervention type: DEVICE
Intervention: Specular Microscope Konan CELLCHEK XL
Description: Konan CELLCHEK XL
Study: NCT03119688

Intervention type: OTHER
Group type: OTHER
Intervention: Test Product
Description: Micellar cleanser (0.09 ml)

Intervention type: OTHER
Group type: OTHER
Intervention: Positive Control
Description: Bar Soap (rubbed for 6 seconds to generate a lather)

Intervention type: OTHER
Group type: OTHER
Intervention: Reference Product
Description: Sterile Water (0.09 ml)

Intervention type: OTHER
Group type: OTHER
Intervention: No Treatment
Description: Unwashed area of the forearm
Study: NCT01907945

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Microclinic Water Program
Description: Three session educational program is delivered to study participants and their self-selected social networks in a group setting. The three session topics are the spread of water borne illness, water treatment methods and social support for sustaining household water treatment. Sessions are taught by a trained community health worker and a study staff member.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Household education
Description: Three session educational program is delivered to study participants at an individual household level. The three session topics are the spread of water borne illness, water treatment methods and social support for sustaining household water treatment. Sessions are taught by a trained community health worker and a study staff member.
Study: NCT00464555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: Will replace antithymocyte globulin in all islet transplantations after the first one

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisofylline
Description: An anti-inflammatory that may reduce the rate at which islet cells die.
Study: NCT02418845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYM-1219
Study: NCT00464555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Maintenance immunosuppressive therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Maintenance immunosuppressive therapy
Study: NCT02418845

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00508274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: Lapatinib ditosylate monohydrate tablets, 250 mg, are oval, biconvex, orange, film-coated tablets taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Capecitabine is supplied as a biconvex, oblong, light peach and peach colored, film-coated tablets for oral administration.